A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation - Full Text View

Sponsored by:	Astellas Pharma Inc
Information provided by:	Astellas Pharma Inc
ClinicalTrials.gov Identifier:	NCT00481819

Purpose

The patients about to undergo kidney transplantation will be randomized to one of the following two group:

Group FK506MR: FK506MR/MMF/steroid; Group Prograf® : Prograf® /MMF/steroid. The treatment period is 3 months( 12 weeks)

Condition	Intervention	Phase
Kidney Transplantation	Drug: FK506MR Drug: Prograf Drug: Mycophenolate Mofetil Drug: Methylprednisolone Drug: Prednisolone	Phase III

Study Type:	Interventional
Study Design:	Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Multicenter, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Combination With MMF and Steroids in Patients Undergoing Kidney Transplantation and a Pharmacokinetics Study.

Resource links provided by NLM:

MedlinePlus related topics: Kidney Transplantation

Drug Information available for: Prednisolone Prednisolone acetate Depo-medrol Medrol veriderm Methylprednisolone Tacrolimus anhydrous Tacrolimus Mycophenolate mofetil hydrochloride Mycophenolate Mofetil Prednisolone sodium phosphate Prednisolone Sodium Succinate Methylprednisolone Sodium Succinate Methylprednisolone hemisuccinate 6-Methylprednisolone

U.S. FDA Resources

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:

Event rate of patients with acute rejections [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Incidence of and time to acute rejections [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
Overall frequency of acute rejections [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
Rate of patient and graft survival following transplantation [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]

Enrollment:	240
Study Start Date:	July 2007
Study Completion Date:	March 2009
Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental In combination with MMF and steroids	Drug: FK506MR oral Drug: Mycophenolate Mofetil oral Drug: Methylprednisolone oral Drug: Prednisolone oral
2: Active Comparator In combination with MMF and steroids	Drug: Prograf oral Drug: Mycophenolate Mofetil oral Drug: Methylprednisolone oral Drug: Prednisolone oral

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Written informed consent with the date of the patient must be obtained.
Patient between 18-70 years of age receiving the primary kidney.
Female patients must have a negative pregnancy test prior to the enrolment.
Female patients of child bearing potential must agree to practice effective birth control during the study.

Exclusion Criteria:

Kidney re-transplantation patients or received an organ transplantation other than a kidney.
PRA>10% in the previous 6 months.
Patient who need antibody induction therapy.
Patient with significant liver disease, defined as having continuously elevated >2 times of SGPT and/or SGOT and/or total bilirubin levels during the past 28 days.
Patient with severe infection requiring treatment, and/or severe diarrhea, vomiting, active upper gastrointestinal tract malabsorption or active peptic ulcer.
Patient has any history of severe cardiovascular, respiratory disease; or history of malignancy.
Patient is HIV or HBsAg positive.
Patient is allergic to Prograf or macrolide antibiotics.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00481819

Locations

China
3 Sites
Beijing, China
2 Sites
Shanghai, China
China, Fujian

Fuzhou, Fujian, China
China, Guangdong
2 Sites
Guangzhou, Guangdong, China
China, Hubei

Wuhan, Hubei, China
China, Hunan

Changsha, Hunan, China
China, Liaoning

Shenyang, Liaoning, China
China, Sichuan

Chongqing, Sichuan, China
China, Zheijiang

Hangzhou, Zheijiang, China

Sponsors and Collaborators

Astellas Pharma Inc

Investigators

Principal Investigator:

Prof. Ao Jianhua

Department of Urologic Surgery

More Information

No publications provided

Responsible Party:	Astellas Pharma, Inc ( Director )
Study ID Numbers:	MR4KTxCN01
Study First Received:	May 31, 2007
Last Updated:	March 10, 2009
ClinicalTrials.gov Identifier:	NCT00481819 History of Changes
Health Authority:	China: State Food and Drug Administration

Keywords provided by Astellas Pharma Inc:

Kidney Transplantation
Tacrolimus
Methylprednisolone
Prednisolone
Mycophenolate Mofetil

Study placed in the following topic categories:

Anti-Inflammatory Agents
Immunologic Factors
Antineoplastic Agents, Hormonal
Methylprednisolone
Hormone Antagonists
Mycophenolic Acid
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Methylprednisolone acetate
Prednisolone acetate

Tacrolimus
Immunosuppressive Agents
Neuroprotective Agents
Glucocorticoids
Hormones
Anti-Bacterial Agents
Prednisolone
Mycophenolate mofetil
Peripheral Nervous System Agents
Methylprednisolone Hemisuccinate

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Methylprednisolone
Antineoplastic Agents
Physiological Effects of Drugs
Mycophenolic Acid
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Prednisolone acetate
Tacrolimus
Antibiotics, Antineoplastic
Hormones
Neuroprotective Agents
Therapeutic Uses

Mycophenolate mofetil
Methylprednisolone Hemisuccinate
Antineoplastic Agents, Hormonal
Gastrointestinal Agents
Methylprednisolone acetate
Enzyme Inhibitors
Glucocorticoids
Protective Agents
Immunosuppressive Agents
Pharmacologic Actions
Autonomic Agents
Prednisolone
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on July 02, 2009